拉替拉韦在妊娠期的药代动力学及安全性 - Suppr

Pharmacokinetic and safety of raltegravir in pregnancy.

作者信息

Croci Leonardo, Trezzi Michele, Allegri Maria Pia, Carli Tiziana, Chigiotti Silvia, Riccardi Maria Piera, Ricciardi Barbara, Toti Mario, Nencioni Cesira

出版信息

Eur J Clin Pharmacol. 2012 Aug;68(8):1231-2. doi: 10.1007/s00228-012-1250-5. Epub 2012 Mar 1.

DOI:10.1007/s00228-012-1250-5

PMID:22382989

Abstract

摘要

相似文献

Pharmacokinetic and safety of raltegravir in pregnancy.拉替拉韦在妊娠期的药代动力学及安全性

Eur J Clin Pharmacol. 2012 Aug;68(8):1231-2. doi: 10.1007/s00228-012-1250-5. Epub 2012 Mar 1.

Rapid reduction in HIV viral load in late pregnancy with raltegravir: a case report.妊娠晚期使用拉替拉韦快速降低HIV病毒载量：一例报告

J Int Assoc Provid AIDS Care. 2013 Sep-Oct;12(5):312-4. doi: 10.1177/2325957413488176. Epub 2013 May 21.

Critical Review: Review of the Efficacy, Safety, and Pharmacokinetics of Raltegravir in Pregnancy.批判性综述：拉替拉韦在孕期的疗效、安全性及药代动力学综述

J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):153-61. doi: 10.1097/QAI.0000000000000932.

A population pharmacokinetics analysis assessing the exposure of raltegravir once-daily 1200 mg in pregnant women living with HIV.评估 HIV 感染者中每日一次服用利匹韦林 1200mg 时的暴露情况的群体药代动力学分析。

CPT Pharmacometrics Syst Pharmacol. 2021 Feb;10(2):161-172. doi: 10.1002/psp4.12586. Epub 2021 Jan 25.

Raltegravir versus lopinavir/ritonavir for treatment of HIV-infected late-presenting pregnant women.拉替拉韦与洛匹那韦/利托那韦治疗晚期就诊的HIV感染孕妇的疗效比较

HIV Clin Trials. 2018 Jun;19(3):94-100. doi: 10.1080/15284336.2018.1459343. Epub 2018 Apr 9.

Therapeutic drug monitoring guided raltegravir dosing for prevention of vertical transmission in a premature neonate born to a woman living with perinatally acquired HIV.治疗药物监测指导下的拉替拉韦给药用于预防一名早产新生儿的垂直传播，该新生儿母亲为围产期感染艾滋病毒的女性。

Antivir Ther. 2017;22(6):545-549. doi: 10.3851/IMP3139. Epub 2017 Feb 15.

FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients.美国食品药品监督管理局通知。美国食品药品监督管理局批准拉替拉韦用于初治的HIV-1感染患者。

AIDS Alert. 2009 Sep;24(9):106-7.

Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir.间断利福平对拉替拉韦的药代动力学及安全性的影响。

J Antimicrob Chemother. 2015 Feb;70(2):550-4. doi: 10.1093/jac/dku376. Epub 2014 Sep 26.

[Use of raltegravir in pregnant HIV-1 infected women: experience in different clinical scenarios].[拉替拉韦在感染HIV-1的孕妇中的应用：不同临床场景下的经验]

Enferm Infecc Microbiol Clin. 2014 Nov;32(9):616-8. doi: 10.1016/j.eimc.2014.01.006. Epub 2014 Feb 17.

Raltegravir pharmacokinetics in neonates following maternal dosing.母亲给药后新生儿中拉替拉韦的药代动力学。

J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):310-5. doi: 10.1097/QAI.0000000000000316.

引用本文的文献

Antiretroviral Therapy Containing Raltegravir to Prevent Mother-to-Child Transmission of HIV in Infected Pregnant Women.含雷特格韦的抗逆转录病毒疗法预防感染HIV的孕妇母婴传播。

Infect Dis Rep. 2017 Jun 14;9(2):7017. doi: 10.4081/idr.2017.7017. eCollection 2017 May 31.

Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy.孕期埃替格韦、度鲁特韦及其他抗逆转录病毒药物的药代动力学和胎盘转运

Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.02213-16. Print 2017 Jun.

Bidirectional Transfer of Raltegravir in an Ex Vivo Human Cotyledon Perfusion Model.雷特格韦在体外人胎盘小叶灌注模型中的双向转运

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3112-4. doi: 10.1128/AAC.00007-16. Print 2016 May.

A case series of third-trimester raltegravir initiation: Impact on maternal HIV-1 viral load and obstetrical outcomes.孕晚期开始使用雷特格韦的病例系列研究：对孕产妇HIV-1病毒载量及产科结局的影响。

Can J Infect Dis Med Microbiol. 2015 May-Jun;26(3):145-50. doi: 10.1155/2015/731043.

Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals.保护胎儿免受艾滋病毒感染：抗逆转录病毒药物胎盘转运的系统评价。

Clin Pharmacokinet. 2014 Nov;53(11):989-1004. doi: 10.1007/s40262-014-0185-7.

Raltegravir pharmacokinetics during pregnancy.孕期拉替拉韦的药代动力学。

J Acquir Immune Defic Syndr. 2014 Dec 1;67(4):375-81. doi: 10.1097/QAI.0000000000000318.

Micronucleated erythrocytes in newborn rats exposed to raltegravir placental transfer.暴露于拉替拉韦胎盘转运的新生大鼠中的微核红细胞。

Biomed Res Int. 2014;2014:851820. doi: 10.1155/2014/851820. Epub 2014 May 25.

本文引用的文献

High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women.在HIV-1阳性孕妇中经胎盘转移后新生儿体内拉替拉韦浓度较高。

AIDS. 2010 Sep 24;24(15):2416-8. doi: 10.1097/QAD.0b013e32833d8a50.

Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy.在一名怀孕38周时出现高水平HIV病毒血症的女性中，在持续的高效抗逆转录病毒治疗基础上加用拉替拉韦和替诺福韦后，HIV-RNA迅速下降。

J Antimicrob Chemother. 2010 Sep;65(9):2050-2. doi: 10.1093/jac/dkq264. Epub 2010 Jul 14.

Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.新型抗逆转录病毒药物达芦那韦和依曲韦林联合或不联合雷特格韦在妊娠期的应用：两例报告

Antivir Ther. 2010;15(4):677-80. doi: 10.3851/IMP1558.

Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice.抗逆转录病毒药物的药代动力学变异性及其与病毒学结果的相关性：两年常规临床实践经验

J Antimicrob Chemother. 2009 Jul;64(1):109-17. doi: 10.1093/jac/dkp132. Epub 2009 Apr 27.

Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.发现雷特格韦，一种有效、选择性口服生物可利用的HIV整合酶抑制剂，用于治疗HIV-艾滋病感染。

J Med Chem. 2008 Sep 25;51(18):5843-55. doi: 10.1021/jm800245z.

Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme.抗艾滋病药物拉替拉韦（MK-0518）在人体内的代谢与处置，该药物作用于人类免疫缺陷病毒1整合酶。

Drug Metab Dispos. 2007 Sep;35(9):1657-63. doi: 10.1124/dmd.107.016196. Epub 2007 Jun 25.

Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation.多药耐药P-糖蛋白（ABCB1糖蛋白）在人胎盘中的表达随孕周增加而降低。

Placenta. 2006 Jun-Jul;27(6-7):602-9. doi: 10.1016/j.placenta.2005.05.007. Epub 2005 Sep 6.

U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States.美国公共卫生服务部特别工作组关于在感染HIV-1的孕妇中使用抗逆转录病毒药物以促进孕产妇健康及采取干预措施减少美国围产期HIV-1传播的建议。

MMWR Recomm Rep. 2002 Nov 22;51(RR-18):1-38; quiz CE1-4.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pharmacokinetic and safety of raltegravir in pregnancy.

作者信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献